Johnson & Johnson Halts $5B-Potential CAR-T Pipeline Amid Strategic Portfolio Realignment

Click on the image to view conference details.↑↑↑

Recently, Johnson & Johnson, a global pharmaceutical giant, announced a major strategic adjustment: the official termination of two core CAR-T cell therapies under development — CD20 single-target CAR-T (JNJ-9530) and CD19/CD20 dual-target CAR-T (JNJ-4496). These two star projects, once expected to reach a peak of $5 billion by 2030, have suddenly come to a halt.

This termination was not due to clinical failure. Johnson & Johnson officially stated that this decision was based on the adjustment of the company's portfolio priorities and a comprehensive evaluation of the evolving treatment landscape for large B-cell lymphoma. The two candidate drugs are currently in Phase 1 and Phase 1/2 clinical trials, respectively. Johnson & Johnson has committed to strictly adhering to the study protocols and will continue to provide full support to patients already enrolled in the trials. No negative signals regarding efficacy or safety have been disclosed.

Tracing back to the origin of the project, it was once seen by Johnson & Johnson as a "sure-win" key investment. In 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, signed a global collaboration agreement with Cellular Biomedicine Group (CBMG), paying an upfront fee of $245 million to secure exclusive development rights for JNJ-4496 (formerly C-CAR039) and JNJ-9530 (formerly C-CAR066) outside of China, as well as the right of first refusal within China. According to the agreement, CBMG is also eligible to receive up to several hundred million dollars in development, regulatory, and sales milestone payments, along with tiered royalties on future product sales, which once became a benchmark for industry cooperation.

At its peak, JNJ-4496 was considered the "ceiling-level" presence in the CAR-T field. In June 2025, Johnson & Johnson announced its Phase 1b clinical data, showing a complete response rate (CRR) of up to 75%-80% in the recommended dose group for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) in second-line and beyond treatments, stunning the entire audience with its efficacy. In September of the same year, at the Morgan Stanley industry event, Dr. John Reed, Head of Johnson & Johnson's R&D, highly praised: "JNJ-4496 demonstrates the best treatment opportunity for similar diseases to date, with the highest complete response rate," and clearly stated that the next step would be to push full speed ahead into Phase 3 clinical trials.

At that time, Johnson & Johnson had already set ambitious goals for it during the 2023 Investor Event: to position this CD20 dual-target CAR-T as a core asset with a planned launch before 2030 and peak sales exceeding $5 billion. It aims to pair this product with its already commercialized BCMA CAR-T product, Carvykti, forming a "dual-ace" CAR-T portfolio to dominate the global cell therapy market.

Now that the vision has fallen through and Johnson & Johnson’s strategic retreat has directly rewritten the competitive landscape of the CAR-T field for large B-cell lymphoma, two CD19/CD20 dual-target CAR-T therapies (KITE-363, KITE-753) from Gilead, which were in phase 1/2 clinical stages, were direct competitors of JNJ-4496. After Johnson & Johnson's withdrawal, Gilead's competitive pressure has significantly decreased. Meanwhile, Chinese pharmaceutical company WuXi AppTec Juno had already released positive phase 1 data for a similar dual-target CAR-T product last year. Now, with a more relaxed competitive environment, the opportunity for China-produced CAR-T to overtake competitors has become even more prominent.

At the industry level, Johnson & Johnson's choice is by no means an isolated case, but rather a collective reassessment by global large pharmaceutical companies of the B-cell lymphoma CAR-T track. Currently, the approved CD19-targeted CAR-T therapies (Yescarta, Breyanzi) have long established efficacy benchmarks, and the market is becoming saturated. Meanwhile, the pain points of traditional autologous CAR-T, such as "customized production, high costs, and difficulty in scaling," are becoming increasingly prominent. The homogenization of target tracks is causing congestion, and the input-output ratio continues to decline.

In response, Johnson & Johnson made it clear: It is not abandoning the CAR-T field but focusing on more promising directions. The company will continue to firmly establish a broad innovative oncology pipeline, prioritizing projects that are "most capable of transforming patient care." Future resources will be further directed towards next-generation technologies such as the BCMA CAR-T Carvykti developed in collaboration with Legend Biotech, off-the-shelf universal CAR-T, and in vivo CAR-T, avoiding the fiercely competitive red ocean of traditional autologous CAR-T.

From astronomical investments, data-driven success to strategic cutbacks, the rise and fall of Johnson & Johnson's CAR-T project epitomizes the cellular therapy industry’s shift from "unbridled growth" to "rational deep cultivation." As the traditional target track’s benefits peak and homogenized competition becomes unsustainable, focusing on technological breakthroughs, reducing treatment costs, and improving patient accessibility are the ultimate paths for the CAR-T industry—this is both the core logic behind Johnson & Johnson's strategic adjustments and the future direction of the global cellular therapy industry.

Source of Information:

https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma

Source: Uncle's Quick Review

*This WeChat Official Account remains neutral on all original and reproduced content, statements, and viewpoint judgments. The shared content is for non-profit purposes only. If any reproduced works or images have incorrect author source markings or involve infringement, original authors are kindly reminded to contact the editor for removal.

*Editorial Responsibility| Mu Yang

*Reprint Permission |Little E 13166175613 (Same number on WeChat))

*Business Cooperation | LiuTeacher13262726197(WeChat same number)